Headquartered in Geneva, Switzerland, Selexis SA is a global life science company with technologies for drug discovery, cell line development and scale-up to manufacturing of therapeutic proteins. The Company is dedicated to the development of innovative technologies and world-class expert services that significantly reduce the time, effort, and costs associated with developing high-performance mammalian cell lines for therapeutic protein production (e.g. monoclonal antibodies, growth factors, enzymes). The Company’s SUREtechnology Platform™ offers comprehensive and rapid solutions for the development of stable and high yield mammalian cell lines. For over 10 years, Selexis has built interactive collaborations, partnerships and commercial deals with leading biotechnology and pharmaceutical companies worldwide. From discovery to Phase II clinical trials, Selexis’ technology has been and is currently being used by more than 50 companies worldwide.